CRIS
Curis, Inc.
Price Chart
Latest Quote
$0.42
+0.01 (+3.69%)
Current Price
| Previous Close | $0.41 |
| Open | $0.38 |
| Day High | $0.45 |
| Day Low | $0.38 |
| Volume | 709,635 |
Stock Information
| Shares Outstanding | 38.98M |
| Total Debt | $1.34M |
| Cash Equivalents | $15.00M |
| Revenue | $7.06M |
| Net Income | $-21.16M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $16.41M |
| EPS (TTM) | $-0.56 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.18M |
| Sales | $7.06M |
| Income | $-21.16M |
| Book/sh | $0.66 |
| Cash/sh | $0.38 |
| Employees | 20 |
Financial Ratios
| Quick Ratio | 0.96 |
| Current Ratio | 1.22 |
| Debt/Eq | 10.52 |
Returns & Margins
| ROA | -62.06% |
| ROE | -693.93% |
| Gross Margin | -270.88% |
| Operating Margin | -485.12% |
| Profit Margin | -299.66% |
Ownership
| Insider Ownership | 8.03% |
| Institutional Ownership | 40.50% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.35 |
| P/S | 2.32 |
| P/B | 0.64 |
Analyst Data
| Recommendation | none |
| Target Price | $14.00 |
Technical Indicators
| SMA20 | $0.47 |
| SMA50 | $0.53 |
| SMA200 | $1.03 |
| RSI | 17.39 |
| ATR | 0.0464 |
| Shares Float | 32.51M |
| Short Float | 0.74% |
| Short Ratio | 1.16 |
| Volatility | 3.08 |
| Rel Volume | 1.97 |
Performance History
| Week | -2.33% |
| Month | -12.50% |
| Quarter | -44.74% |
| 6 Months | -64.41% |
| YTD | -57.14% |
| Year | -82.20% |
| 3 Years | -97.34% |
| 5 Years | -99.74% |
| 10 Years | -99.73% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.42 | 898,600 |
| 2026-06-17 | $0.41 | 4,236,600 |
| 2026-06-16 | $0.38 | 639,000 |
| 2026-06-15 | $0.42 | 168,100 |
| 2026-06-12 | $0.42 | 128,500 |
| 2026-06-11 | $0.43 | 104,500 |
| 2026-06-10 | $0.43 | 154,300 |
| 2026-06-09 | $0.45 | 258,300 |
| 2026-06-08 | $0.47 | 284,200 |
| 2026-06-05 | $0.47 | 340,500 |
| 2026-06-04 | $0.50 | 65,900 |
| 2026-06-03 | $0.50 | 165,400 |
| 2026-06-02 | $0.50 | 119,000 |
| 2026-06-01 | $0.52 | 292,100 |
| 2026-05-29 | $0.57 | 362,300 |
| 2026-05-28 | $0.52 | 221,200 |
| 2026-05-27 | $0.53 | 196,200 |
| 2026-05-26 | $0.49 | 134,700 |
| 2026-05-22 | $0.50 | 104,900 |
| 2026-05-21 | $0.49 | 228,000 |
| 2026-05-20 | $0.50 | 125,200 |
| 2026-05-19 | $0.48 | 160,700 |
About Curis, Inc.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
đ° Latest News
Curis (CRIS) Q1 2026 Earnings Call Transcript
Motley Fool âĸ 2026-06-02T17:20:24Z
Curis, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-13T12:30:00Z
Curis Inc (CRIS) Q1 2026 Earnings Call Highlights: Progress in Lymphoma Study and Financial ...
GuruFocus.com âĸ 2026-05-13T05:02:19ZVericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-07T15:15:09Z
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-04-28T12:45:02Z
Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock?
Zacks âĸ 2026-04-15T16:00:03Z
Curis Inc (CRIS) Q4 2025 Earnings Call Highlights: A Turnaround with Strong Quarterly Profit ...
GuruFocus.com âĸ 2026-03-20T03:02:01ZCuris, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-20T00:12:30Z
Curis (CRIS) Q4 2025 Earnings Call Transcript
Motley Fool âĸ 2026-03-19T21:37:20Z
Curis: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-19T20:11:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $45,000 | $98,000 | $212,000 | $257,000 |
| Total Revenue | $9,443,000 | $10,908,000 | $10,023,000 | $10,162,000 |
| Operating Revenue | $9,443,000 | $10,908,000 | $10,023,000 | $10,162,000 |
| Expenses | ||||
| Interest Expense | $2,185,000 | $615,000 | $2,019,000 | $4,771,000 |
| Total Expenses | $42,345,000 | $55,450,000 | $58,355,000 | $63,182,000 |
| Other Income Expense | $27,189,000 | - | - | - |
| Net Non Operating Interest Income Expense | $-1,869,000 | $1,153,000 | $919,000 | $-3,652,000 |
| Interest Expense Non Operating | $2,185,000 | $615,000 | $2,019,000 | $4,771,000 |
| Operating Expense | $42,300,000 | $55,352,000 | $58,143,000 | $62,925,000 |
| General And Administrative Expense | $14,046,000 | $16,790,000 | $18,647,000 | $19,648,000 |
| Rent Expense Supplemental | - | - | - | - |
| Other Non Operating Income Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-7,582,000 | $-43,389,000 | $-47,413,000 | $-56,672,000 |
| Net Interest Income | $-1,869,000 | $1,153,000 | $919,000 | $-3,652,000 |
| Interest Income | $316,000 | $1,768,000 | $2,938,000 | $1,119,000 |
| Normalized Income | $-34,771,000 | $-43,389,000 | $-47,413,000 | $-56,672,000 |
| Net Income From Continuing And Discontinued Operation | $-7,582,000 | $-43,389,000 | $-47,413,000 | $-56,672,000 |
| Total Operating Income As Reported | $-5,713,000 | $-44,542,000 | $-48,332,000 | $-53,020,000 |
| Net Income Common Stockholders | $-7,582,000 | $-43,389,000 | $-47,413,000 | $-56,672,000 |
| Net Income | $-7,582,000 | $-43,389,000 | $-47,413,000 | $-56,672,000 |
| Net Income Including Noncontrolling Interests | $-7,582,000 | $-43,389,000 | $-47,413,000 | $-56,672,000 |
| Net Income Continuous Operations | $-7,582,000 | $-43,389,000 | $-47,413,000 | $-56,672,000 |
| Pretax Income | $-7,582,000 | $-43,389,000 | $-47,413,000 | $-56,672,000 |
| Special Income Charges | $27,189,000 | $0 | - | - |
| Interest Income Non Operating | $316,000 | $1,768,000 | $2,938,000 | $1,119,000 |
| Operating Income | $-32,902,000 | $-44,542,000 | $-48,332,000 | $-53,020,000 |
| Gross Profit | $9,398,000 | $10,810,000 | $9,811,000 | $9,905,000 |
| Per Share | ||||
| Diluted EPS | $-0.58 | $-6.88 | $-8.96 | $-12.20 |
| Basic EPS | $-0.58 | $-6.88 | $-8.96 | $-12.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-32,417,000 | $-42,571,000 | $-45,139,000 | $-51,668,000 |
| Total Unusual Items | $27,189,000 | $0 | - | - |
| Total Unusual Items Excluding Goodwill | $27,189,000 | $0 | - | - |
| Reconciled Depreciation | $169,000 | $203,000 | $255,000 | $233,000 |
| EBITDA (Bullshit earnings) | $-5,228,000 | $-42,571,000 | $-45,139,000 | $-51,668,000 |
| EBIT | $-5,397,000 | $-42,774,000 | $-45,394,000 | $-51,901,000 |
| Diluted Average Shares | $13,164,032 | $6,306,284 | $5,293,294 | $4,669,625 |
| Basic Average Shares | $13,164,032 | $6,306,284 | $5,293,294 | $4,669,625 |
| Diluted NI Availto Com Stockholders | $-7,582,000 | $-43,389,000 | $-47,413,000 | $-56,672,000 |
| Other Special Charges | $-27,189,000 | - | - | - |
| Research And Development | $28,254,000 | $38,562,000 | $39,496,000 | $43,277,000 |
| Selling General And Administration | $14,046,000 | $16,790,000 | $18,647,000 | $19,648,000 |
| Other Gand A | $6,583,000 | $7,164,000 | $8,408,000 | $7,839,000 |
| Insurance And Claims | $741,000 | $904,000 | $1,068,000 | $1,405,000 |
| Salaries And Wages | $6,722,000 | $8,722,000 | $9,171,000 | $10,404,000 |
| Rent And Landing Fees | - | - | - | - |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-3,520,000 | $-14,980,000 | $10,688,000 | $37,570,000 |
| Total Assets | $19,966,000 | $41,265,000 | $77,282,000 | $108,848,000 |
| Total Non Current Assets | $13,051,000 | $14,880,000 | $16,374,000 | $16,729,000 |
| Other Non Current Assets | $2,117,000 | $2,504,000 | $3,902,000 | $2,657,000 |
| Goodwill And Other Intangible Assets | $8,982,000 | $8,982,000 | $8,982,000 | $8,982,000 |
| Current Assets | $6,915,000 | $26,385,000 | $60,908,000 | $92,119,000 |
| Other Current Assets | $1,854,000 | $3,039,000 | $1,780,000 | $3,521,000 |
| Receivables | $0 | $3,349,000 | $2,794,000 | $2,975,000 |
| Accounts Receivable | $0 | $3,349,000 | $2,794,000 | $2,975,000 |
| Cash Cash Equivalents And Short Term Investments | $5,061,000 | $19,997,000 | $56,334,000 | $85,623,000 |
| Cash And Cash Equivalents | $5,061,000 | $19,997,000 | $26,681,000 | $19,658,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $1,618,000 | $2,954,000 | $2,794,000 | $3,941,000 |
| Long Term Debt And Capital Lease Obligation | $428,000 | $1,618,000 | $1,489,000 | $2,800,000 |
| Current Debt And Capital Lease Obligation | $1,190,000 | $1,336,000 | $1,305,000 | $1,141,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $14,504,000 | $47,263,000 | $57,612,000 | $62,296,000 |
| Total Non Current Liabilities Net Minority Interest | $428,000 | $28,236,000 | $35,591,000 | $52,283,000 |
| Current Liabilities | $14,076,000 | $19,027,000 | $22,021,000 | $10,013,000 |
| Payables And Accrued Expenses | $12,886,000 | $10,135,000 | $12,212,000 | $8,872,000 |
| Payables | $5,612,000 | $3,024,000 | $3,172,000 | $3,193,000 |
| Accounts Payable | $5,612,000 | $3,024,000 | $3,172,000 | $3,193,000 |
| Other Non Current Liabilities | - | $26,618,000 | $34,102,000 | $49,483,000 |
| Other Current Liabilities | - | $7,556,000 | $8,504,000 | - |
| Equity | ||||
| Common Stock Equity | $5,462,000 | $-5,998,000 | $19,670,000 | $46,552,000 |
| Total Equity Gross Minority Interest | $5,462,000 | $-5,998,000 | $19,670,000 | $46,552,000 |
| Stockholders Equity | $5,462,000 | $-5,998,000 | $19,670,000 | $46,552,000 |
| Retained Earnings | $-1,247,381,000 | $-1,239,799,000 | $-1,196,410,000 | $-1,148,997,000 |
| Gains Losses Not Affecting Retained Earnings | - | $0 | $229,000 | $-186,000 |
| Other Equity Adjustments | - | - | $229,000 | $-186,000 |
| Other | ||||
| Ordinary Shares Number | $12,928,853 | $8,487,818 | $5,894,085 | $4,830,379 |
| Share Issued | $12,928,853 | $8,487,818 | $5,894,085 | $4,830,379 |
| Tangible Book Value | $-3,520,000 | $-14,980,000 | $10,688,000 | $37,570,000 |
| Invested Capital | $5,462,000 | $-5,998,000 | $19,670,000 | $46,552,000 |
| Working Capital | $-7,161,000 | $7,358,000 | $38,887,000 | $82,106,000 |
| Capital Lease Obligations | $1,618,000 | $2,954,000 | $2,794,000 | $3,941,000 |
| Total Capitalization | $5,462,000 | $-5,998,000 | $19,670,000 | $46,552,000 |
| Additional Paid In Capital | $1,252,714,000 | $1,233,716,000 | $1,215,792,000 | $1,195,687,000 |
| Capital Stock | $129,000 | $85,000 | $59,000 | $48,000 |
| Common Stock | $129,000 | $85,000 | $59,000 | $48,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $428,000 | $1,618,000 | $1,489,000 | $2,800,000 |
| Current Capital Lease Obligation | $1,190,000 | $1,336,000 | $1,305,000 | $1,141,000 |
| Current Accrued Expenses | $7,274,000 | $7,111,000 | $9,040,000 | $5,679,000 |
| Goodwill | $8,982,000 | $8,982,000 | $8,982,000 | $8,982,000 |
| Net PPE | $1,952,000 | $3,394,000 | $3,490,000 | $5,090,000 |
| Accumulated Depreciation | $-851,000 | $-1,013,000 | $-1,991,000 | $-2,457,000 |
| Gross PPE | $2,803,000 | $4,407,000 | $5,481,000 | $7,547,000 |
| Leases | $214,000 | $257,000 | $257,000 | $257,000 |
| Other Properties | $1,890,000 | $3,163,000 | $3,056,000 | $4,401,000 |
| Machinery Furniture Equipment | $699,000 | $987,000 | $2,168,000 | $2,889,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | - | $0 | $29,653,000 | $65,965,000 |
| Treasury Shares Number | - | - | $0 | - |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | $3,152,000 |
| Investments And Advances | - | - | - | $0 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-27,201,000 | $-39,563,000 | $-38,434,000 | $-54,753,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-27,201,000 | $-39,563,000 | $-38,434,000 | $-54,337,000 |
| Cash Flow From Continuing Operating Activities | $-27,201,000 | $-39,563,000 | $-38,434,000 | $-54,337,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $2,500,000 | $29,442,000 | $37,786,000 | $33,023,000 |
| Cash Flow From Continuing Investing Activities | $2,500,000 | $29,442,000 | $37,786,000 | $33,023,000 |
| Capital Expenditure | - | - | - | $-416,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $15,352,000 | $12,023,000 | $14,117,000 | $5,842,000 |
| Financing Cash Flow | $9,765,000 | $3,437,000 | $7,580,000 | $867,000 |
| Cash Flow From Continuing Financing Activities | $9,765,000 | $3,437,000 | $7,580,000 | $867,000 |
| Net Other Financing Charges | $-5,587,000 | $-8,586,000 | $-6,537,000 | $-4,975,000 |
| Net Common Stock Issuance | $15,352,000 | $12,023,000 | $14,117,000 | $5,842,000 |
| Common Stock Issuance | $15,352,000 | $12,023,000 | $14,117,000 | $5,842,000 |
| Other | ||||
| Interest Paid Supplemental Data | $1,534,000 | $461,000 | $2,359,000 | $4,112,000 |
| End Cash Position | $5,605,000 | $20,541,000 | $27,225,000 | $20,293,000 |
| Beginning Cash Position | $20,541,000 | $27,225,000 | $20,293,000 | $40,740,000 |
| Changes In Cash | $-14,936,000 | $-6,684,000 | $6,932,000 | $-20,447,000 |
| Net Investment Purchase And Sale | $0 | $29,442,000 | $37,786,000 | $33,439,000 |
| Sale Of Investment | $0 | $47,540,000 | $108,126,000 | $95,439,000 |
| Purchase Of Investment | $0 | $-18,098,000 | $-70,340,000 | $-62,000,000 |
| Net Business Purchase And Sale | $2,500,000 | $0 | - | - |
| Sale Of Business | $2,500,000 | $0 | - | - |
| Change In Working Capital | $1,750,000 | $-3,716,000 | $2,779,000 | $-6,818,000 |
| Change In Other Current Liabilities | $-1,336,000 | $-1,223,000 | $-1,147,000 | $-907,000 |
| Change In Payables And Accrued Expense | $2,546,000 | $-2,077,000 | $3,340,000 | $-3,884,000 |
| Change In Prepaid Assets | $1,572,000 | $139,000 | $405,000 | $-2,276,000 |
| Change In Receivables | $-1,032,000 | $-555,000 | $181,000 | $249,000 |
| Changes In Account Receivables | $-1,032,000 | $-555,000 | $181,000 | $249,000 |
| Other Non Cash Items | $-25,556,000 | $1,428,000 | $1,004,000 | $1,817,000 |
| Stock Based Compensation | $4,018,000 | $5,927,000 | $6,000,000 | $6,752,000 |
| Amortization Of Securities | $0 | $-16,000 | $-1,059,000 | $351,000 |
| Depreciation Amortization Depletion | $169,000 | $203,000 | $255,000 | $233,000 |
| Depreciation And Amortization | $169,000 | $203,000 | $255,000 | $233,000 |
| Net Income From Continuing Operations | $-7,582,000 | $-43,389,000 | $-47,413,000 | $-56,672,000 |
| Net PPE Purchase And Sale | - | - | $0 | $-416,000 |
| Purchase Of PPE | - | - | $0 | $-416,000 |
| Proceeds From Stock Option Exercised | - | - | - | $248,000 |
| Change In Other Current Assets | - | - | - | $-2,022,000 |
| Change In Payable | - | - | - | $-3,884,000 |
| Change In Account Payable | - | - | - | $-3,884,000 |
| Repayment Of Debt | - | - | - | - |
| Issuance Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Gain Loss On Sale Of PPE | - | - | - | - |
Fetched: 2026-06-15